Preeclampsia More Than 1 Disease

Abstract

HomeHypertensionVol. 51, No. 4Preeclampsia More Than 1 Disease Free AccessEditorialPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessEditorialPDF/EPUBPreeclampsia More Than 1 DiseaseOr Is It? James M. Roberts and Janet M. Catov James M. RobertsJames M. Roberts From the Magee-Womens Research Institute, Department of Obstetrics, Gynecology, & Reproductive Sciences and Epidemiology, University of Pittsburgh School of Medicine, Pa. Search for more papers by this author and Janet M. CatovJanet M. Catov From the Magee-Womens Research Institute, Department of Obstetrics, Gynecology, & Reproductive Sciences and Epidemiology, University of Pittsburgh School of Medicine, Pa. Search for more papers by this author Originally published7 Feb 2008https://doi.org/10.1161/HYPERTENSIONAHA.107.100248Hypertension. 2008;51:989–990Other version(s) of this articleYou are viewing the most recent version of this article. Previous versions: February 7, 2008: Previous Version 1 In this issue of Hypertension, Rasmussen and Irgens provide strong support for the relationship of preeclampsia and intrauterine growth restriction (IUGR). They also provide data that support but also some that argue against the concept that the pregnancy complication, preeclampsia, may be more than one disease.1 In previous studies these authors demonstrated that women who have had a growth-restricted infant without preeclampsia are more likely to have preeclampsia in a subsequent pregnancy.2Those data and similar findings in the current study support pathological findings indicating the similarity of IUGR and preeclampsia.3 In preeclampsia, IUGR and interestingly also in about one third of cases of preterm birth,4 the maternal myometrial and decidual vessels perfusing the placental site do not undergo the normal remodeling of pregnancy. In normal pregnancy trophoblastic invasion is associated with a greatly increased diameter and removal of vascular smooth muscle from the wall of these vessels. This results in large diameter, flaccid, unresponsive tubes that greatly increase placental perfusion. These changes are not present in pregnancies complicated by IUGR, preeclampsia, and some with preterm births. Implicit in the current study is the concept that preterm birth as well as IUGR is related to subsequent preeclampsia. Although preterm birth is not assessed directly, the effect of low birth weight (IUGR and preterm birth) was greater than the effect of IUGR alone. In a far smaller study our group was able to more directly support the relationship of preterm birth and preeclampsia, as women with early onset preeclampsia were more likely to have preterm birth in a subsequent nonpreeclamptic pregnancy.5The current study extends the prior observation of the relationship of IUGR and preeclampsia but also raises other interesting points. In this larger study the authors were able to determine a “dose response” for reduced growth, demonstrating that the smaller the baby the greater the odds ratio for a subsequent pregnancy with preeclampsia. Although this is what might be expected, what is not as straightforward was the fact that small babies increased the risk of early onset and severe preeclampsia more than they increased the risk for “mild” preeclampsia occurring at the end of pregnancy. This difference in the effect on different degrees of preeclampsia supports numerous observations suggesting that early onset preeclampsia may be a different disease than preeclampsia occurring at term. There are abundant epidemiological observations indicating differences in recurrence rates and relationship to later life cardiovascular disease. The authors of the current manuscript previously examined the database used in this study to test the relationship of preeclampsia to later-life cardiovascular mortality. A median of 14 years after a first pregnancy, women with preeclampsia before 37 weeks gestation had 8 times more cardiovascular deaths than women with normal pregnancy. For women with preeclampsia at term, the increase was only 1.7-fold.6 The likelihood that preeclampsia will recur is almost 60% for early onset preeclampsia,7 whereas it is 10% to 20% for preeclampsia near term.8Pathophysiological markers are also different. For example, antiangiogenic factors are much better predictors of early onset preeclampsia than late onset disease.9 Also, whereas early preeclampsia is associated with an excess of small babies, late onset does not share that relationship and there is actually an excess of larger babies.10 The data presented in the current Rasmussen study support a concept that early preeclampsia is associated with reduced placental perfusion and is a different disease than preeclampsia at term in which reduced perfusion may not be a major component (Figure, Panel 1). The authors suggest this may indicate a different genetic origin for the disorder that occurs early and late. Download figureDownload PowerPointFigure. Genesis of early and late onset preeclampsia. Panel 1 indicates early and late preeclampsia as disorders with two different origins, with only preterm preeclampsia being related to reduced perfusion. Panel 2 illustrates a common origin, reduced placental perfusion, and “maternal constitutional factors” (genetic, behavioral, or environmental factors). Preeclampsia can result with minimal maternal contribution and primarily reduced perfusion (A) with a relatively similar contribution of both factors (B) or with predominantly an increased maternal sensitivity with minimal (? no) reduced perfusion.Their data, however, also support an alternative explanation. Several years ago we expanded on a concept introduced by the Oxford Group that preeclampsia was a 2-stage disorder.11 The first stage was proposed to be reduced placental perfusion, and the second the maternal response to this reduced perfusion. In this model reduced placental perfusion could result in IUGR or preterm birth (or both) but the maternal syndrome of preeclampsia would only occur in women in whom “constitutional factors” (genetics, behavior, environment, etc) rendered the mother sensitive to the effects of reduced placental perfusion. The findings in the Rasmussen study also provide support for this hypothesis. In this study it appears that such constitutional factors might evolve over time. At the time of the first pregnancy these constitutional factors were not sufficient to cause maternal disease in response to reduced placental perfusion, only IUGR or preterm birth resulted. However, by the time of the second pregnancy maternal constitutional factors were sufficient to result in preeclampsia. This progression of maternal sensitivity to reduced perfusion is supported by the finding that the relationship of IUGR to subsequent preeclampsia increased with lengthening interpregnancy interval. Further support for the role of maternal genes and constitution was the observation that it was only the mother and not the father who conferred the risk of preeclampsia to a second pregnancy.This model of maternal fetal interaction provides an alternative explanation for the heterogeneous presentation of preeclampsia early and late other than 2 different diseases. The Figure (panel 2) indicates preeclampsia as one disease with different manifestations depending on the relative contribution from maternal constitution and reduced fetal placental perfusion. Thus, profoundly reduced perfusion (A) results in preeclampsia in virtually any woman and would be accompanied by IUGR. Lesser degrees of reduced perfusion (B) might result in IUGR with or without preeclampsia depending on the maternal constitution whereas in the profoundly sensitive woman minimally reduced perfusion (or perhaps merely the results of normal perfusion) are sufficient to lead to preeclampsia (C).Which is the appropriate model? We would suggest both. The genesis of reduced perfusion is very different than what might cause the posited increased response to reduced perfusion. From a genetic perspective, maternal and fetal (paternal) genes contributing to reduced placental perfusion are likely quite different than those rendering the woman sensitive to the putative results of reduced perfusion. Interestingly, many of these maternal constitutional factors or genetic factors that increase the risk of preeclampsia, eg, obesity, lipid abnormalities, black race, and metabolic syndrome are also risks for later life cardiovascular disease. The data in the current study indicate a further level of complexity. In this study early onset preeclampsia, the variety of preeclampsia most associated with later life cardiovascular disease, is the form best predicted by IUGR, the marker of reduced perfusion. It appears that not only are the constitutional factors associated with the maternal response but that they may also be associated with abnormal implantation, failed vascular remodeling, and reduced placental perfusion. Preterm birth without preeclampsia in work by the same group predicts cardiovascular disease better than term preeclampsia.6 In addition, habitual abortion associated with similar abnormalities of placental bed vascular remodeling but with no maternal syndrome of preeclampsia is also associated with abnormal endothelial function long after delivery.12 These data suggest that at least some of the constitutional factors leading to the maternal preeclampsia syndrome in response to reduced placental perfusion can also contribute to reduced perfusion.Is the identification of subtypes of preeclampsia important? We would suggest it is vitally important. Whether the differences are qualitative or quantitative the finding in this and other studies suggest the same end point can be reached by different routes. This concept is supported by the consistent observation that whatever linkage between reduced perfusion and maternal disease is suggested, eg, oxidative stress, excess antiangiogenic factors, increased endogenous antagonists of nitric oxide, or autoantibodies that activate the angiotensin II receptor type 1, none of these is increased in all preeclamptic women. We would urge investigators to be cognizant of this (as are the authors of the Rasmussen article) and to look for and pay attention to differences in logical subsets of preeclamptic women. Analogous to diabetes, a disorder originally ascribed solely to one cause, insulinopenia, progress in understanding, preventing, and treating preeclampsia would be enormously aided by the identification of subsets of disease, which take a different pathway to a fairly nonspecific diagnosis of new onset hypertension in pregnancy.The opinions expressed in this editorial are not necessarily those of the editors or of the American Heart Association.Sources of FundingSupport for this work was funded by NIH P01 HD30367.DisclosuresNone.FootnotesCorrespondence to James M. Roberts, MD, Senior Scientist, Magee-Womens Research Institute, Professor of Obstetrics, Gynecology & Reproductive Sciences and Epidemiology, Graduate School of Public Health, University of Pittsburgh School of Medicine, 204 Craft Avenue, Pittsburgh, PA 15213. E-mail [email protected] References 1 Rasmussen S, Irgens LM. History of fetal growth restriction is more strongly associated with severe rather than milder pregnancy-induced hypertension. Hypertension. 2008; 51: 1231–1238.LinkGoogle Scholar2 Rasmussen S, Irgens LM, Albrechtsen S, Dalaker K. Predicting preeclampsia in the second pregnancy from low birth weight in the first pregnancy. Obstet Gynecol. 2000; 96: 696–700.MedlineGoogle Scholar3 Khong TY, De Wolf F, Robertson WB, Brosens I. Inadequate maternal vascular response to placentation in pregnancies complicated by pre-eclampsia and by small-for-gestational age infants. Br J Obstet Gynaecol. 1986; 93: 1049–1059.CrossrefMedlineGoogle Scholar4 Arias F, Rodriquez L, Rayne SC, Kraus FT. Maternal placental vasculopathy and infection: Two distinct subgroups among patients with preterm labor and preterm ruptured membranes. Am J Obstet Gynaecol. 1993; 168: 585–591.CrossrefMedlineGoogle Scholar5 Lain KY, Krohn MA, Roberts JM. Second pregnancy outcomes following preeclampsia in a first pregnancy. Hypertens Pregnancy. 2005; 24: 159–169.CrossrefMedlineGoogle Scholar6 Irgens HU, Reisaeter L, Irgens LM, Lie RT. Long term mortality of mothers and fathers after pre-eclampsia: population based cohort study. BMJ. 2001; 323: 1213–1217.CrossrefMedlineGoogle Scholar7 Sibai BM, Mercer B, Sarinoglu C. Severe preeclampsia in the second trimester: recurrence risk and long-term prognosis. Am J Obstet Gynecol. 1991; 165: 1408–1412.CrossrefMedlineGoogle Scholar8 Caritis S, Sibai B, Hauth J, Lindheimer MD, Klebanoff M, Thom E, VanDorsten P, Landon M, Paul R, Miodovnik M, Meis P. Thurnau, G. et al. Low-dose aspirin to prevent preeclampsia in women at high risk. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. N Engl J Med. 1998; 338: 701–705.CrossrefMedlineGoogle Scholar9 Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA. Circulating angiogenic factors and the risk of preeclampsia.[see comment]. N Engl J Med. 2004; 350: 672–683.CrossrefMedlineGoogle Scholar10 Xiong X, Demianczuk NN, Buekens P, Saunders LD. Association of preeclampsia with high birth weight for gestational age. Am J Obstet Gynecol. 2000; 183: 148–155.CrossrefMedlineGoogle Scholar11 Roberts JM, Gammill HS. Preeclampsia: recent insights. Hypertension. 2005; 46: 1243–1249.LinkGoogle Scholar12 Germain AM, Romanik MC, Guerra I, Solari S, Reyes MS, Johnson RJ, Price K, Karumanchi SA, Valdes G. Endothelial dysfunction: a link among preeclampsia, recurrent pregnancy loss, and future cardiovascular events?[see comment]. Hypertension. 2007; 49: 90–95.LinkGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Sala M, Romero M, Romero A, Fasano M, Varea A, Carrera P, Salazar M, Espeche W and González H (2021) Neurodevelopmental assessment of infants born to mothers with hypertensive disorder of pregnancy at six months of age, Journal of Developmental Origins of Health and Disease, 10.1017/S204017442100026X, 13:2, (197-203), Online publication date: 1-Apr-2022. Wiles K, Chappell L, Lightstone L and Bramham K (2020) Updates in Diagnosis and Management of Preeclampsia in Women with CKD, Clinical Journal of the American Society of Nephrology, 10.2215/CJN.15121219, 15:9, (1371-1380), Online publication date: 7-Sep-2020. Herraiz García I, Llurba Olive E, Galindo Izquierdo A and Verlohren S (2019) Actualización del diagnóstico y el pronóstico de la preeclampsia en embarazos únicos con la ayuda del cociente sFlt-1/PlGF, Progresos de Obstetricia y Ginecología, 10.20960/j.pog.00061, . Salazar M, Espeche W, Balbín E, Leiva Sisnieguez C, Leiva Sisnieguez B, Stavile R, March C, Olano R, Soria A, Yoma O, Prudente M, Torres S, Grassi F, Santillan C, Carrera Ramos P and Carbajal H (2019) Office blood pressure values and the necessity of out-of-office measurements in high-risk pregnancies, Journal of Hypertension, 10.1097/HJH.0000000000002140, 37:9, (1838-1844), Online publication date: 1-Sep-2019. Marques M, Grandi C, Nascente L, Cavalli R and Cardoso V (2018) Placental morphometry in hypertensive disorders of pregnancy and its relationship with birth weight in a Latin American population, Pregnancy Hypertension, 10.1016/j.preghy.2018.06.020, 13, (235-241), Online publication date: 1-Jul-2018. Alsnes I, Vatten L, Fraser A, Bjørngaard J, Rich-Edwards J, Romundstad P and Åsvold B (2017) Hypertension in Pregnancy and Offspring Cardiovascular Risk in Young Adulthood, Hypertension, 69:4, (591-598), Online publication date: 1-Apr-2017. Iwahashi N, Yamamoto M, Nanjo S, Toujima S, Minami S and Ino K (2017) Downregulation of indoleamine 2, 3-dioxygenase expression in the villous stromal endothelial cells of placentas with preeclampsia, Journal of Reproductive Immunology, 10.1016/j.jri.2017.01.003, 119, (54-60), Online publication date: 1-Feb-2017. Porto L, Brandão A, Leite H and Cabral A (2017) Longitudinal evaluation of uterine perfusion, endothelial function and central blood flow in early onset pre-eclampsia, Pregnancy Hypertension, 10.1016/j.preghy.2017.08.005, 10, (161-164), Online publication date: 1-Oct-2017. Salazar M, Espeche W, Leiva Sisnieguez B, Balbín E, Leiva Sisnieguez C, Stavile R, March C, Grassi F, Santillan C, Cor S and Carbajal H (2016) Significance of masked and nocturnal hypertension in normotensive women coursing a high-risk pregnancy, Journal of Hypertension, 10.1097/HJH.0000000000001067, 34:11, (2248-2252), Online publication date: 1-Nov-2016. Roy S, Dhobale M, Dangat K, Mehendale S, Lalwani S and Joshi S (2015) Differential oxidative stress levels in mothers with preeclampsia delivering male and female babies, The Journal of Maternal-Fetal & Neonatal Medicine, 10.3109/14767058.2014.974537, 28:16, (1973-1980), Online publication date: 2-Nov-2015. Myatt L and Roberts J (2015) Preeclampsia: Syndrome or Disease?, Current Hypertension Reports, 10.1007/s11906-015-0595-4, 17:11, Online publication date: 1-Nov-2015. Katsipi I, Stylianou K, Petrakis I, Passam A, Vardaki E, Parthenakis F, Makrygiannakis A, Daphnis E and Kyriazis J (2014) The use of pulse wave velocity in predicting pre-eclampsia in high-risk women, Hypertension Research, 10.1038/hr.2014.62, 37:8, (733-740), Online publication date: 1-Aug-2014. Herraiz I, Dröge L, Gómez-Montes E, Henrich W, Galindo A and Verlohren S (2014) Characterization of the Soluble fms-Like Tyrosine Kinase-1 to Placental Growth Factor Ratio in Pregnancies Complicated by Fetal Growth Restriction, Obstetrics & Gynecology, 10.1097/AOG.0000000000000367, 124:2, (265-273), Online publication date: 1-Aug-2014. Rasmussen S, Irgens L and Espinoza J (2014) Maternal obesity and excess of fetal growth in pre-eclampsia, BJOG: An International Journal of Obstetrics & Gynaecology, 10.1111/1471-0528.12677, 121:11, (1351-1358), Online publication date: 1-Oct-2014. Betoni J, Derr K, Pahl M, Rogers L, Muller C, Packard R, Carey D, Kuivaniemi H and Tromp G (2013) MicroRNA analysis in placentas from patients with preeclampsia: comparison of new and published results, Hypertension in Pregnancy, 10.3109/10641955.2013.807819, 32:4, (321-339), Online publication date: 1-Nov-2013. Gómez-Arriaga P, Herraiz I, López-Jiménez E, Gómez-Montes E, Denk B and Galindo A (2013) Uterine artery Doppler and sFlt-1/PlGF ratio: usefulness in diagnosis of pre-eclampsia, Ultrasound in Obstetrics & Gynecology, 10.1002/uog.12400, 41:5, (530-537), Online publication date: 1-May-2013. Sundrani D, Reddy U, Joshi A, Mehendale S, Chavan-Gautam P, Hardikar A, Chandak G and Joshi S (2013) Differential placental methylation and expression of VEGF, FLT- 1 and KDR genes in human term and preterm preeclampsia, Clinical Epigenetics, 10.1186/1868-7083-5-6, 5:1, Online publication date: 1-Dec-2013. Herraiz I, Escribano D, Gómez-Arriaga P, Herníndez-García J, Herraiz M and Galindo A (2012) Predictive value of sequential models of uterine artery Doppler in pregnancies at high risk for pre-eclampsia, Ultrasound in Obstetrics & Gynecology, 10.1002/uog.10147, 40:1, (68-74), Online publication date: 1-Jul-2012. Dieber-Rotheneder M, Beganovic S, Desoye G, Lang U and Cervar-Zivkovic M (2012) Complex expression changes of the placental endothelin system in early and late onset preeclampsia, fetal growth restriction and gestational diabetes, Life Sciences, 10.1016/j.lfs.2012.04.040, 91:13-14, (710-715), Online publication date: 1-Oct-2012. Myatt L, Clifton R, Roberts J, Spong C, Hauth J, Varner M, Wapner R, Thorp J, Mercer B, Grobman W, Ramin S, Carpenter M, Samuels P, Sciscione A, Harper M, Tolosa J, Saade G, Sorokin Y and Anderson G (2012) The Utility of Uterine Artery Doppler Velocimetry in Prediction of Preeclampsia in a Low-Risk Population, Obstetrics & Gynecology, 10.1097/AOG.0b013e31826af7fb, 120:4, (815-822), Online publication date: 1-Oct-2012. Wu C, Nohr E, Bech B, Vestergaard M, Catov J and Olsen J (2011) Diseases in children born to mothers with preeclampsia: a population-based sibling cohort study, American Journal of Obstetrics and Gynecology, 10.1016/j.ajog.2010.08.046, 204:2, (157.e1-157.e5), Online publication date: 1-Feb-2011. Kulkarni A, Chavan-Gautam P, Mehendale S, Yadav H and Joshi S (2011) Global DNA Methylation Patterns in Placenta and Its Association with Maternal Hypertension in Pre-Eclampsia, DNA and Cell Biology, 10.1089/dna.2010.1084, 30:2, (79-84), Online publication date: 1-Feb-2011. Ducray J, Naicker T and Moodley J (2011) Pilot study of comparative placental morphometry in pre-eclamptic and normotensive pregnancies suggests possible maladaptations of the fetal component of the placenta, European Journal of Obstetrics & Gynecology and Reproductive Biology, 10.1016/j.ejogrb.2010.12.038, 156:1, (29-34), Online publication date: 1-May-2011. Thornton C, von Dadelszen P, Makris A, Tooher J, Ogle R and Hennessy A (2009) Acute Pulmonary Oedema as a Complication of Hypertension During Pregnancy, Hypertension in Pregnancy, 10.3109/10641950902972140, 30:2, (169-179), Online publication date: 1-May-2011. Eskild A and Vatten L (2010) Do pregnancies with pre-eclampsia have smaller placentas? A population study of 317 688 pregnancies with and without growth restriction in the offspring, BJOG: An International Journal of Obstetrics & Gynaecology, 10.1111/j.1471-0528.2010.02701.x, 117:12, (1521-1526), Online publication date: 1-Nov-2010. (2010) Risk factors, predictors, and future management Placental Bed Disorders, 10.1017/CBO9780511750847.020, (195-242) Eskild A, Romundstad P and Vatten L (2009) Placental weight and birthweight: does the association differ between pregnancies with and without preeclampsia?, American Journal of Obstetrics and Gynecology, 10.1016/j.ajog.2009.06.003, 201:6, (595.e1-595.e5), Online publication date: 1-Dec-2009. Pettersson A, Richiardi L, Cnattingius S, Kaijser M and Akre O (2008) Gestational Hypertension, Preeclampsia, and Risk of Testicular Cancer, Cancer Research, 10.1158/0008-5472.CAN-08-2309, 68:21, (8832-8836), Online publication date: 1-Nov-2008. Herraiz I, Simón E, Gómez-Arriaga P, Martínez-Moratalla J, García-Burguillo A, Jiménez E and Galindo A (2015) Angiogenesis-Related Biomarkers (sFlt-1/PLGF) in the Prediction and Diagnosis of Placental Dysfunction: An Approach for Clinical Integration, International Journal of Molecular Sciences, 10.3390/ijms160819009, 16:8, (19009-19026) Ghaemi M, Tarca A, Romero R, Stanley N, Fallahzadeh R, Tanada A, Culos A, Ando K, Han X, Blumenfeld Y, Druzin M, El-Sayed Y, Gibbs R, Winn V, Contrepois K, Ling X, Wong R, Shaw G, Stevenson D, Gaudilliere B, Aghaeepour N and Angst M (2021) Proteomic signatures predict preeclampsia in individual cohorts but not across cohorts – implications for clinical biomarker studies, The Journal of Maternal-Fetal & Neonatal Medicine, 10.1080/14767058.2021.1888915, (1-8) April 2008Vol 51, Issue 4 Advertisement Article InformationMetrics https://doi.org/10.1161/HYPERTENSIONAHA.107.100248PMID: 18259043 Originally publishedFebruary 7, 2008 PDF download Advertisement SubjectsClinical StudiesHypertension